Apellis Pharmaceuticals, Inc. (FRA:1JK)

Market Cap	2.39B -34.0%
Revenue (ttm)	866.28M +42.1%
Net Income	38.34M
EPS	0.31
Shares Out	n/a
PE Ratio	62.41
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8
Open	18.73
Previous Close	18.12
Day's Range	18.73 - 18.73
52-Week Range	13.88 - 27.18
Beta	n/a
RSI	52.51
Earnings Date	Feb 25, 2026

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem ce...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 708
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1JK

Financial Performance

In 2024, Apellis Pharmaceuticals's revenue was $781.37 million, an increase of 97.02% compared to the previous year's $396.59 million. Losses were -$197.88 million, -62.57% less than in 2023.

Financial numbers in USD